Cleveland BioLabs Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cleveland BioLabs Inc CBLI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 5.26 04:00:15
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
5.10 5.14 0.04 - -
Trades Volume Avg Volume 52 Week Range
1 3 91,672 1.60 - 10.9718
Last Trade Time Type Quantity Stock Price Currency
04:05:08 3 $ 5.14 USD

Cleveland BioLabs Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 81.37M 15.47M 8.93M $ 262.94k $ - -0.19 -29.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 23.70%

more financials information »

Cleveland BioLabs News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CBLI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.805.854.755.18103,139-0.54-9.31%
1 Month5.225.904.755.4188,1420.040.77%
3 Months5.407.174.215.68113,977-0.14-2.59%
6 Months3.1210.97182.855.61278,0252.1468.59%
1 Year1.7410.97181.603.621,127,9063.52202.3%
3 Years2.468610.97180.503.44498,1392.79113.08%
5 Years2.526310.97180.503.59380,4612.73108.21%

Cleveland BioLabs Description

Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.

Your Recent History
Cleveland ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.